Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.185    -0.005 (-2.63%)
Bid:
0.18
Ask:
0.19
Spread: 0.01 (5.556%)
Market Cap: £1.37m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Convertible Loan Note Offer

18 Jul 2006 15:48

Azure Holdings PLC18 July 2006 Azure Holdings plc (the "Company") Convertible Loan Note Offer The Company announces that it has today issued a letter to holders of ordinaryshares of 1p each in the Company ("Ordinary Shares"), on the share register ofthe Company on 17 July 2006, offering them the opportunity to participate in thesubscription of up to £1,200,000 nominal unsecured convertible loan stock 2008("Loan Stock"). The Loan Stock is being offered following discussions regarding a proposedacquisition by the Company ("Acquisition"). The proposed target for theAcquisition is ValiRX Limited ("ValiRX"), a biopharmaceutical developmentcompany. Discussions with ValiRX are progressing and the directors of theCompany hope to complete a reverse takeover under the AIM rules before 30September 2006. The principal terms of the Loan Stock are as follows: 1 Unless previously converted or repaid, the Loan Stock isrepayable 24 months from the date of the Loan Stock instrument under which it iscreated (the "Instrument") or at any time after 31 October 2006 at the Company'soption. 2 In partial consideration for the Loan Stock holderssubscribing for Loan Stock, a premium ("Premium") of £2 for each £1 nominal ofLoan Stock is payable, unless previously converted or paid, 24 months from thedate of the Instrument, or at any time after 31 October 2006 at the Company'soption. 3 Interest is payable from 1 November 2006 on the amount ofthe Loan Stock at the rate of two per cent. over the base rate of the Bank ofScotland plc from time to time. Interest is payable twice yearly. The firstinterest period will run from 1 November 2006 to 31 March 2007. 4 The conversion of Loan Stock ("Conversion") into OrdinaryShares is conditional upon approval by shareholders of resolutions to allotshares and disapply pre-emption rights; and if appropriate, the approval by avote of independent shareholders taken on a poll of any waiver granted by thePanel on Takeovers and Mergers of any obligation under rule 9 of the City Codeon Takeovers and Mergers which may arise from such Conversion (together the "Conversion Event") 5 Immediately prior to the Conversion Event, the Loan Stockis deemed repayable and the Premium is deemed payable. 6 On the Conversion Event, the Loan Stock and the Premiumwhich has not been repaid or paid as the case may be, will be converted intoOrdinary Shares in the capital of the Company at the rate of 100 Ordinary Sharesof the Company for each £1 otherwise due for repayment or payment. 7 So far as it is lawfully able to do so, the Company willnotify the Loan Stock holders at least 10 days in advance of the likelyoccurrence of the Conversion Event. 8 The Loan Stock is transferable in multiples of £10,000. 9 The Company is obliged to repay the Loan Stock and pay thePremium on the occurrence of certain events, including certain insolvencyevents. 10 Decisions relating to the Loan Stock are to be taken by a writtenresolution of the holders of at least two thirds in nominal value of theoutstanding Loan Stock. Applications for the Loan Stock may only be made for a minimum of £1,000 nominaland in multiples of £1,000. Applications for the Loan Stock are to be receivedby the Company at One Great Cumberland Place, London W1H 7AL by 3.00pm on 31July 2006. A copy of the letter despatched to shareholders and the Instrument are availablefor inspection, on request, at Halliwells LLP, 1 Threadneedle Street, LondonEC2R 8AW during normal business hours on any weekdays, Saturdays, Sundays andpublic holidays excluded, for one month from today. For further information, please contact: Barry Gold, Azure Holdings plcTel: 07768 948 928 David Youngman, WH Ireland Limited Tel: 0161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
15th Jan 202512:47 pmRNSHolding(s) in Company
15th Jan 202511:29 amRNSHolding(s) in Company
14th Jan 20257:00 amRNSHolding(s) in Company
9th Jan 202511:37 amRNSHolding(s) in Company
9th Jan 202511:14 amRNSHolding(s) in Company
8th Jan 20257:00 amRNSHolding(s) in Company
2nd Jan 202511:45 amRNSHolding(s) in Company
31st Dec 20241:06 pmRNSHolding(s) in Company
31st Dec 20248:39 amRNSUpdate on proposed sub-license of VAL201
30th Dec 20241:30 pmRNSResult of GM, Issue of Equity, Warrants and TVR
20th Dec 20247:00 amRNS-RValiRx launches new interactive investor website
10th Dec 20244:45 pmRNSBroker Offer Results & Director/PDMR Subscription
10th Dec 20243:03 pmRNSPosting of Circular and Notice of General Meeting
9th Dec 20247:00 amRNSConditional Fundraising & Launch of Broker Offer
22nd Nov 20247:00 amRNSInaphaea award of HEIF Funding and PhD sponsorship
20th Nov 20247:00 amRNSUpdate on proposed sub-license of VAL401
19th Nov 20247:00 amRNSContract Award
18th Nov 20247:00 amRNSFirst Sale of New Product Line
30th Oct 20247:00 amRNSUpdate on proposed sub-license of VAL201
18th Oct 20247:00 amRNSDirectorate Change
14th Oct 20247:00 amRNSInvestor Webinar
7th Oct 20247:00 amRNSInaphaea Co-Marketing Agreement
27th Sep 20247:00 amRNSHalf-year Report
26th Sep 20247:00 amRNSConclusion of Evaluation Project
24th Sep 20247:00 amRNSInaphaea Co-Marketing Agreement
18th Sep 20247:00 amRNSInaphaea Evaluation and Commercial Use Agreement
16th Sep 20247:00 amRNSInaphaea Co-Marketing Agreement
9th Sep 20247:00 amRNSInaphaea Evaluation and Commercial Use Agreement
9th Sep 20247:00 amRNSInvestor Evening
27th Aug 20247:00 amRNSInaphaea Evaluation and Commercial Use Agreement
12th Aug 20247:00 amRNSDirectorate Change
25th Jul 20247:00 amRNSDirectorate Changes
3rd Jul 20248:51 amRNSProposed Director Appointment
20th Jun 20245:56 pmRNSResult of AGM
19th Jun 202411:33 amRNSDirectorate Change
17th Jun 20247:00 amRNSInaphaea Contract Award
28th May 20247:00 amRNSInvestor Webinar
20th May 202412:00 pmRNSBusiness Update
16th May 20247:00 amRNSFurther re Final Results
15th May 20247:00 amRNSFinal Results and Notice of AGM
22nd Apr 20247:00 amRNSDirectorate Changes
21st Mar 20247:00 amRNSEvaluation Agreement with Imperial College London
19th Mar 20247:00 amRNSBoard Re-structuring and update on requisition
4th Mar 20245:47 pmRNSShareholder Requisition Notice
4th Mar 20247:00 amRNSProposed Appointment of Non-Executive Director
29th Feb 20242:00 pmRNSProposed Appointment of Non-Executive Director
13th Feb 20242:20 pmRNSFurther re Shareholder Requisition Notice
9th Feb 20245:06 pmRNSShareholder Requisition Notice
19th Jan 20247:00 amRNSChange of Broker
18th Jan 20247:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.